EAACI 2022: CCDs impact ImmunoCAP but not NOVEOS test results

NOVEOS System by HYCOR was mentioned in the following abstracts and scientific posters at The European Academy of Allergy and Clinical Immunology congress held on 1-3 July, 2022 at Prague, Czech Republic and online.

New research presented at the Annual Hybrid Congress of EAACI 2022 show Cross-reactive carbohydrate determinants (CCDs) impact ImmunoCAP but not NOVEOS test results when assayed for six (6) different allergens. The assay design of NOVEOS is unaffected by biotin or cellulose-based CCD interference; and the small 4 μL sample volume per test leads to less interference from serum-based substances. Simply put -NOVEOS system is an automated platform with an improved specificity and sensitivity in sIgE detection. Learn More about the Groundbreaking NOVEOS immunoassay system, The NEW STANDARD in IgE allergy testing.

Study title:

Cross-reactive carbohydrate determinants (CCDs) impact ImmunoCAP but not NOVEOS test results when assayed with six (6) different allergens

Authors: A. Salimi, C. Skevaki, et. al.

Objective:

To compare overall performance of NOVEOS, a new blood allergy system to other established immunoassay systems (i.e. Phadia)

Conclusions:

Researchers confirmed the overall good analytical performance of the NOVEOS allergen sIgE assay vs. ImmunoCAP. The NOVEOS system is an automated platform with an improved specificity and sensitivity sIgE detection, and thus an alternative diagnostic tool for routine laboratory testing. Additionally, it was demonstrated that CCDs impacted ImmunoCAP but not NOVEOS results.

EAACI Hybrid Congress 2022 is the world’s largest congress specializing in the field of allergy and clinical immunology.

»Download the Cross-Reactive Carbohydrate Determinants (CCD) Interference Brochure and NOVEOS